Beta Bionics Q2 FY26 net loss widens 39% to $23.4 million; net sales climb 38% to $32 million
BBNX•Q2 FY26 results
Beta Bionics posted a GAAP net loss of $23.4 million, widening 39% year over year for the quarter ended June 30, 2026.
GAAP net sales climbed 38% to $32 million, driven by higher single-use product volumes tied to installed base growth.
Liquidity position
Cash, cash equivalents, short-term and long-term investments totaled $225.2 million as of June 30, 2026; funding runway is projected through the first half of 2028.
Margin and channel mix
Gross margin improved 5 percentage points to 59%, reflecting increased production scale, lower warranty expense, and improved cost absorption.
Sales mix shifted toward pharmacy, with the PBP channel at 36% of net sales versus 20% a year earlier on expanded PBM coverage.
